Working… Menu

A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients (COSMOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02034747
Recruitment Status : Completed
First Posted : January 13, 2014
Last Update Posted : November 30, 2018
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Korea, Inc. )

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 7, 2015
Actual Study Completion Date : November 7, 2015